Go Pro
NASDAQ:GRML

Greenland Mines Ltd. Common Stock Q4 2025 Earnings Report

Greenland Mines Ltd. Common Stock logo
$0.23 0.00 (0.00%)
As of 07/2/2026 04:00 PM Eastern

Greenland Mines Ltd. Common Stock EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Greenland Mines Ltd. Common Stock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Greenland Mines Ltd. Common Stock Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Greenland Mines Ltd. Common Stock Earnings Headlines

Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
See More Greenland Mines Ltd. Common Stock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Greenland Mines Ltd. Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenland Mines Ltd. Common Stock and other key companies, straight to your email.

About Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

View Greenland Mines Ltd. Common Stock Profile